Form 4: Xencor SVP & CSO Exercises Options, Sells Shares

Xencor's Senior Vice President and Chief Scientific Officer, John R. Desjarlais, exercised stock options and subsequently sold a portion of the acquired shares.

Summary

• John R. Desjarlais, Xencor's SR. VICE PRESIDENT & CSO, engaged in multiple transactions involving company stock.
• On December 19, 2025, Desjarlais exercised options to acquire 73,367 shares of common stock at an exercise price of $12.51 per share.
• Concurrently on December 19, 2025, he sold all 73,367 shares acquired from the option exercise at a weighted average price of $15.72 per share, with prices ranging from $15.51 to $15.97.
• On December 22, 2025, Desjarlais exercised additional options to acquire 6,311 shares of common stock at an exercise price of $12.51 per share.
• The option exercises represented expiring grants, with a vesting schedule that began on January 26, 2016, and fully vested on its four-year anniversary.
• Following these transactions, Desjarlais's direct beneficial ownership of common stock increased to 242,885 shares after the final exercise on December 22, 2025.
• His beneficial ownership of derivative securities (stock options) decreased to 5,322 after both exercises.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the insider sale of a significant number of shares, even though it was preceded by an option exercise. While the exercise itself is neutral to positive (indicating value), the net effect of the sale reduces insider ownership, which can sometimes be viewed with caution by investors. However, it's a common event for expiring options and could be for personal financial planning.

Positives

• The exercise of options at $12.51 and subsequent sale at a weighted average of $15.72 indicates a profit for the reporting person on the sold shares.
• The exercise of options, even if followed by a sale, demonstrates the value of the company's equity compensation program.

Negatives

• The sale of 73,367 shares by a Senior Vice President and Chief Scientific Officer could be interpreted negatively by investors as a reduction in insider holdings.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing, which primarily reports insider transactions.

Industry Context

This filing details a routine insider transaction involving the exercise of expiring stock options and a subsequent sale of a portion of the acquired shares. Such transactions are common in the biotechnology industry, where executive compensation often includes equity components designed to align management interests with shareholder value over the long term. The sale of shares, while reducing direct insider holdings, is often part of a pre-arranged trading plan (Rule 10b5-1) or for personal financial planning, and does not necessarily reflect a change in the company's fundamental prospects or broader industry trends.

Comparison to Industry Standards

• Not applicable. This Form 4 reports specific insider transactions for Xencor Inc. and does not provide data for comparison to global benchmarks, comparable companies, or projects.

Related Party Transactions

• The reported transactions involve an executive officer of Xencor Inc., John R. Desjarlais, exercising stock options and selling shares. These are standard insider transactions and not unusual related party dealings beyond the scope of typical executive compensation and share ownership.

Stakeholder Impact

• Shareholders: The sale of shares by a senior executive could lead to minor concerns about insider confidence, though the profit realized from the option exercise might be viewed positively.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The reporting person may engage in further transactions as options expire or for other financial planning purposes.
• Investors will monitor future insider transaction filings for Xencor Inc. to gauge ongoing insider sentiment.

Key Dates

Recommendation

While the insider sale by a senior executive could be a minor negative signal, it's a common occurrence, especially when options are expiring and executives seek to realize gains or manage personal finances. The profit from the option exercise indicates a positive return for the executive. Without additional context from other company filings (e.g., earnings reports, strategic updates), this Form 4 alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. A 'hold' stance is appropriate, pending further fundamental analysis of Xencor Inc.'s overall performance and outlook.

Keywords

Xencor, XNCR, insider trading, Form 4, stock options, share sale, executive compensation, John R. Desjarlais, beneficial ownership